Vanguard Group Inc. Acquires 93,107 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Vanguard Group Inc. grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 1.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,721,360 shares of the biopharmaceutical company's stock after acquiring an additional 93,107 shares during the period. Vanguard Group Inc. owned about 9.14% of Intra-Cellular Therapies worth $811,928,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Cerity Partners LLC grew its stake in shares of Intra-Cellular Therapies by 62.9% during the 3rd quarter. Cerity Partners LLC now owns 44,107 shares of the biopharmaceutical company's stock worth $3,227,000 after acquiring an additional 17,027 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Intra-Cellular Therapies by 1.3% in the third quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company's stock worth $1,614,000 after purchasing an additional 283 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intra-Cellular Therapies by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company's stock valued at $1,648,000 after purchasing an additional 2,622 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Intra-Cellular Therapies by 3.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company's stock valued at $23,649,000 after buying an additional 11,104 shares in the last quarter. Finally, Captrust Financial Advisors boosted its holdings in Intra-Cellular Therapies by 47.0% in the 3rd quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company's stock worth $589,000 after buying an additional 2,572 shares during the period. Hedge funds and other institutional investors own 92.33% of the company's stock.

Remove Ads

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock remained flat at $131.87 during trading hours on Thursday. The business has a fifty day moving average of $129.53 and a 200-day moving average of $101.03. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.98. The stock has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ITCI. Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and reduced their price target for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Needham & Company LLC reiterated a "hold" rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com began coverage on shares of Intra-Cellular Therapies in a report on Friday, March 28th. They issued a "hold" rating on the stock. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Piper Sandler reissued a "neutral" rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $106.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.